WO2018050046A1 - 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 - Google Patents
稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 Download PDFInfo
- Publication number
- WO2018050046A1 WO2018050046A1 PCT/CN2017/101364 CN2017101364W WO2018050046A1 WO 2018050046 A1 WO2018050046 A1 WO 2018050046A1 CN 2017101364 W CN2017101364 W CN 2017101364W WO 2018050046 A1 WO2018050046 A1 WO 2018050046A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- compound
- substituted
- pharmaceutically acceptable
- Prior art date
Links
- 0 CC12C3(*(*C4)I)C4(C*)C1(*)C(*)(*)C(C)(*)C2(*)*3 Chemical compound CC12C3(*(*C4)I)C4(C*)C1(*)C(*)(*)C(C)(*)C2(*)*3 0.000 description 6
- CQZFWRSOFUBQPM-MADGBJHVSA-N C=C[C@]12[C@@H](C3)[C@](CC(O)=O)(C[N+]([O-])=O)[C@H]1C[C@@H]3C2 Chemical compound C=C[C@]12[C@@H](C3)[C@](CC(O)=O)(C[N+]([O-])=O)[C@H]1C[C@@H]3C2 CQZFWRSOFUBQPM-MADGBJHVSA-N 0.000 description 1
- OGMKICMZLXWWTN-YYTIQOGPSA-N CCOC(/C=C(/[C@@H]1C)\[C@@H](CC[C@]2(C)C=N)[C@H]1C2=C)=O Chemical compound CCOC(/C=C(/[C@@H]1C)\[C@@H](CC[C@]2(C)C=N)[C@H]1C2=C)=O OGMKICMZLXWWTN-YYTIQOGPSA-N 0.000 description 1
- UWMDXZXRSUXIGN-BBJCOLAGSA-N CCOC(C[C@](C[N+]([O-])=O)([C@@H]1C)[C@@H](CC[C@H]2C)[C@H]1C2=C)=O Chemical compound CCOC(C[C@](C[N+]([O-])=O)([C@@H]1C)[C@@H](CC[C@H]2C)[C@H]1C2=C)=O UWMDXZXRSUXIGN-BBJCOLAGSA-N 0.000 description 1
- FDODYXQLTLDOLP-YLEBHWOPSA-N CCOC(C[C@](C[N+]([O-])=O)([C@@H]1C)[C@@H]2C1C1=C[C@@H]1CC2)=O Chemical compound CCOC(C[C@](C[N+]([O-])=O)([C@@H]1C)[C@@H]2C1C1=C[C@@H]1CC2)=O FDODYXQLTLDOLP-YLEBHWOPSA-N 0.000 description 1
- XQCQPMXFOJZSIX-BQUFFADESA-N C[C@]([C@@]1(C2=C[C@@H]2CC[C@@H]11)[I]=C)(C11OCCO1)[I]=C Chemical compound C[C@]([C@@]1(C2=C[C@@H]2CC[C@@H]11)[I]=C)(C11OCCO1)[I]=C XQCQPMXFOJZSIX-BQUFFADESA-N 0.000 description 1
- SLYVTRPJEYBEOM-UXMQXVNQSA-N C[C@]1(C2)CC[C@@H]3[C@@](CC(O)=O)(CN)[C@H]2[C@@H]3C1 Chemical compound C[C@]1(C2)CC[C@@H]3[C@@](CC(O)=O)(CN)[C@H]2[C@@H]3C1 SLYVTRPJEYBEOM-UXMQXVNQSA-N 0.000 description 1
- YNUPPIRYRMAQCZ-IRCOFANPSA-N NCC[C@H](C1)[C@H]2[C@@H](CCC(O)=O)CC[C@@H]1C2 Chemical compound NCC[C@H](C1)[C@H]2[C@@H](CCC(O)=O)CC[C@@H]1C2 YNUPPIRYRMAQCZ-IRCOFANPSA-N 0.000 description 1
- HKZFLSDIKUZPHW-UXMQXVNQSA-N NC[C@]1(CC(O)=O)[C@@H](CC2)[C@@H](C3)[C@H]1C[C@]23C#N Chemical compound NC[C@]1(CC(O)=O)[C@@H](CC2)[C@@H](C3)[C@H]1C[C@]23C#N HKZFLSDIKUZPHW-UXMQXVNQSA-N 0.000 description 1
- ZQOSWEWLHVYOEO-WEDXCCLWSA-N O=C(CC1)[C@H]([C@@H]2CCBr)[C@@H]1C21OCCO1 Chemical compound O=C(CC1)[C@H]([C@@H]2CCBr)[C@@H]1C21OCCO1 ZQOSWEWLHVYOEO-WEDXCCLWSA-N 0.000 description 1
- XJPBWXJOMSEWFS-RNJXMRFFSA-N O=C([C@H]1CCBr)[C@H]2[C@@H]1C=CC2 Chemical compound O=C([C@H]1CCBr)[C@H]2[C@@H]1C=CC2 XJPBWXJOMSEWFS-RNJXMRFFSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
实施例编号 | IC50(nM) |
1 | 9.17 |
4 | 10.7 |
6 | 20 |
7 | 53 |
Claims (12)
- 一种通式(I)所示的化合物,或者其立体异构体、溶剂化物、代谢产物、前药、药学上可接受的盐或共晶:其中:R1与R4相结合形成-(CR9R9’)n-或者-CR9=CR9’-;R1’、R2、R3、R3’、R4’、R5、R5’、R6、R9或R9’各自独立地选自H、F、Cl、Br、I、羟基、氨基、羧基、羧酸酯基、酰胺基、氰基、C1-6烷基、C1-6烷氧基、C1-6硫烷基、C2-6烯基、C2-6炔基、3至6元碳环基或者3至6元杂环基,所述的烷基、烷氧基、硫烷基、烯基、炔基、碳环基或者杂环基任选进一步被0至6个选自F、Cl、Br、I、羟基、氨基、羧基、C1-6烷基、3至6元碳环基或者3至6元杂环基所取代,所述的杂环基含有1至2个选自N、O或者S的杂原子;n选自1、2或者3;作为选择,R3与R3’、R5与R5’或者R9与R9’任意一组与其连接的碳原子一起形成所述的任选进一步被0至2个选自F、Cl、Br、I、C1-6烷基、3至6元碳环基或者3至6元杂环基所取代,所述的烷基、3至6元碳环基或者3至6元杂环基任选进一步被0至6个选自F、Cl、Br、I、羟基、氨基、羧基、C1-6烷基、3至6元碳环基或者3至6元杂环基所取代;作为选择,R3与R3’、R5与R5’或者R9与R9’任意一组与其连接的碳原子一起形成3至6元碳环基,所述的碳环基任选进一步被0至6个选自F、Cl、Br、I、羟基、氨基、C1-6烷基、C1-6烷氧基或者C1-6硫烷基所取代;R7选自H、C1-6烷基或者氨基保护基;R8选自H、C1-6烷基或者羧基保护基。
- 根据权利要求1~5任意一项所述的化合物,或者其立体异构体、溶剂化物、代谢产物、前药、药学上可接受的盐或共晶,其中所述的盐选自苯磺酸盐、对甲苯磺酸盐或甲磺酸盐。
- 一种药物组合物,所述药物组合物包含权利要求1至6中任一项所述的化合物或其立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶或者前药,和一种或者多种药学上可接受的载体和/或赋形剂。
- 权利要求7所述的药物组合物或者权利要求1至6任一项所述的化合物或其立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶或者前药在制备用于治疗和/或预防疼痛的药物中的用途。
- 根据权利要求8所述的在制备用于治疗和/或预防疼痛的药物中的用途,所述的疼痛包括:疱疹后神经痛、三叉神经痛、偏头痛、与骨关节炎或关节风湿病相关的疼痛、下背疼痛、坐骨神经痛、牙痛、由烧伤引起的疼痛、由糖尿病性神经病引起的疼痛、由化疗诱导的神经病变引起的疼痛、与HIV相关的神经痛、与AIDS相关的神经痛、与癌症相关的神经痛或非神经痛、急性或慢性紧张性头痛、手术后疼痛或纤维肌痛。
- 一种用于制备通式(I)化合物的中间体,或者其立体异构体和药学上可接受的盐,其中:R1与R4相结合形成-(CR9R9’)n-或者-CR9=CR9’-;R1’、R2、R3、R3’、R4’、R5、R5’、R6、R9或R9’各自独立地选自H、F、Cl、Br、I、羟基、氨基、羧基、羧酸酯基、酰胺基、氰基、C1-6烷基、C1-6烷氧基、C1-6硫烷基、C2-6烯基、C2-6炔基、3至6元碳环基或者3至6元杂环基,所述的烷基、烷氧基、硫烷基、烯基、炔基、碳环基或者杂环基任选进一步被0至6个选自F、Cl、Br、I、羟基、氨基、羧基、C1-6烷基、3至6元碳环基或者3至6元杂环基所取代,所述的杂环基含有1至2个选自N、O或者S的杂原子;n选自1、2或者3;作为选择,R3与R3’、R5与R5’或者R9与R9’任意一组与其连接的碳原子一起形成所述的任选进一步被0至2个选自F、Cl、Br、I、C1-6烷基、3至6元碳环基或者3至6元杂环基所取代,所述的烷基、3至6元碳环基或者3至6元杂环基任选进一步被0至6个选自F、Cl、Br、I、羟基、氨基、羧基、C1-6烷基、3至6元碳环基或者3至6元杂环基所取代;作为选择,R3与R3’、R5与R5’或者R9与R9’任意一组与其连接的碳原子一起形成3至6元碳环基,所述的碳环基任选进一步被0至6个选自F、Cl、Br、I、羟基、氨基、C1-6烷基、C1-6烷氧基或者C1-6硫烷基所取代。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17850248.0A EP3527552B1 (en) | 2016-09-14 | 2017-09-12 | Fused tricyclic gamma-amino acid derivative, preparation method therefore, and medical use thereof |
KR1020197008206A KR102335089B1 (ko) | 2016-09-14 | 2017-09-12 | 융합 트리사이클릭 γ-아미노산 유도체, 그 제조방법, 및 그것의 의료 용도 |
AU2017325913A AU2017325913B2 (en) | 2016-09-14 | 2017-09-12 | Fused tricyclic Γ-amino acid derivative, preparation method therefor, and medical use thereof |
EA201990455A EA036525B1 (ru) | 2016-09-14 | 2017-09-12 | Конденсированное трициклическое производное -аминокислоты, способ его получения и его медицинское применение |
ES17850248T ES2939260T3 (es) | 2016-09-14 | 2017-09-12 | Derivado de gamma-aminoácido tricíclico condensado, método de preparación del mismo y uso médico del mismo |
US16/330,847 US10654794B2 (en) | 2016-09-14 | 2017-09-12 | Fused tricyclic Γ-amino acid derivative, preparation method therefor, and medical use thereof |
BR112019004860-0A BR112019004860B1 (pt) | 2016-09-14 | 2017-09-12 | Compostos, estereoisômeros, solvatos, pró-fármacos ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica contendo os mesmos, uso dos referidos compostos e composto intermediário |
JP2019514102A JP7001679B2 (ja) | 2016-09-14 | 2017-09-12 | 縮合3環γ-アミノ酸誘導体及びその製造方法、並びに医薬における応用 |
CA3035121A CA3035121C (en) | 2016-09-14 | 2017-09-12 | Fused tricyclic .gamma.-amino acid derivative, preparation method therefor, and medical use thereof |
CN201780033351.4A CN109195945B (zh) | 2016-09-14 | 2017-09-12 | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
MX2019002915A MX2019002915A (es) | 2016-09-14 | 2017-09-12 | Derivado de ?-aminoacido triciclico fusionado, metodo de preparacion, y su uso medico del mismo. |
MYPI2019000602A MY196788A (en) | 2016-09-14 | 2017-09-12 | Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof |
ZA2019/01861A ZA201901861B (en) | 2016-09-14 | 2019-03-26 | Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610825611 | 2016-09-14 | ||
CN201610825611.9 | 2016-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018050046A1 true WO2018050046A1 (zh) | 2018-03-22 |
Family
ID=61619859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/101364 WO2018050046A1 (zh) | 2016-09-14 | 2017-09-12 | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US10654794B2 (zh) |
EP (1) | EP3527552B1 (zh) |
JP (1) | JP7001679B2 (zh) |
KR (1) | KR102335089B1 (zh) |
CN (1) | CN109195945B (zh) |
AU (1) | AU2017325913B2 (zh) |
CA (1) | CA3035121C (zh) |
EA (1) | EA036525B1 (zh) |
ES (1) | ES2939260T3 (zh) |
MX (1) | MX2019002915A (zh) |
MY (1) | MY196788A (zh) |
PT (1) | PT3527552T (zh) |
TW (1) | TWI662015B (zh) |
WO (1) | WO2018050046A1 (zh) |
ZA (1) | ZA201901861B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020011257A1 (zh) * | 2018-07-12 | 2020-01-16 | 四川海思科制药有限公司 | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 |
WO2020011258A1 (zh) * | 2018-07-12 | 2020-01-16 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用 |
WO2020029762A1 (zh) * | 2018-08-09 | 2020-02-13 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的制备方法及中间体 |
WO2020155952A1 (zh) * | 2019-02-01 | 2020-08-06 | 四川海思科制药有限公司 | 一种稠合三环衍生物的制备方法及中间体 |
WO2020155953A1 (zh) * | 2019-01-30 | 2020-08-06 | 四川海思科制药有限公司 | 一种稠合三环氘代衍生物及其组合物和应用 |
CN111517930A (zh) * | 2019-02-01 | 2020-08-11 | 四川海思科制药有限公司 | 一种稠合三环衍生物制备方法及中间体 |
CN111517932A (zh) * | 2019-02-01 | 2020-08-11 | 四川海思科制药有限公司 | 一种稠合三环衍生物制备方法及中间体 |
WO2021043117A1 (zh) * | 2019-09-03 | 2021-03-11 | 四川海思科制药有限公司 | 2-((1s,2s,3r,6s,8s)-2-(氨甲基)三环[4.2.1.03,8]壬烷-2-基)乙酸苯磺酸盐或其组合物杂质检测方法 |
WO2022017364A1 (zh) | 2020-07-20 | 2022-01-27 | 四川海思科制药有限公司 | 一种稠合三环γ-氨基酸衍生物的缓释药物制剂及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111517939B (zh) * | 2019-02-01 | 2023-03-31 | 四川海思科制药有限公司 | 一种稠合三环衍生物制备方法及中间体 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1720219A (zh) * | 2001-04-19 | 2006-01-11 | 沃纳-兰伯特公司 | 稠合二环或三环氨基酸 |
CN101878193A (zh) * | 2007-09-28 | 2010-11-03 | 第一三共株式会社 | 双环γ-氨基酸衍生物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA12504A (en) * | 2001-04-19 | 2006-05-29 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids. |
JP5250363B2 (ja) | 2008-09-26 | 2013-07-31 | 京セラドキュメントソリューションズ株式会社 | テキスト入力システム及びテキスト入力プログラム |
WO2010079668A1 (ja) | 2009-01-08 | 2010-07-15 | 第一三共株式会社 | オレフィン化合物 |
WO2010084798A1 (ja) * | 2009-01-21 | 2010-07-29 | 第一三共株式会社 | 3環性化合物 |
WO2017107907A1 (zh) | 2015-12-25 | 2017-06-29 | 四川海思科制药有限公司 | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
-
2017
- 2017-09-12 AU AU2017325913A patent/AU2017325913B2/en active Active
- 2017-09-12 WO PCT/CN2017/101364 patent/WO2018050046A1/zh unknown
- 2017-09-12 MY MYPI2019000602A patent/MY196788A/en unknown
- 2017-09-12 CA CA3035121A patent/CA3035121C/en active Active
- 2017-09-12 JP JP2019514102A patent/JP7001679B2/ja active Active
- 2017-09-12 KR KR1020197008206A patent/KR102335089B1/ko active IP Right Grant
- 2017-09-12 PT PT178502480T patent/PT3527552T/pt unknown
- 2017-09-12 EP EP17850248.0A patent/EP3527552B1/en active Active
- 2017-09-12 CN CN201780033351.4A patent/CN109195945B/zh active Active
- 2017-09-12 MX MX2019002915A patent/MX2019002915A/es unknown
- 2017-09-12 ES ES17850248T patent/ES2939260T3/es active Active
- 2017-09-12 EA EA201990455A patent/EA036525B1/ru unknown
- 2017-09-12 US US16/330,847 patent/US10654794B2/en active Active
- 2017-09-13 TW TW106131443A patent/TWI662015B/zh active
-
2019
- 2019-03-26 ZA ZA2019/01861A patent/ZA201901861B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1720219A (zh) * | 2001-04-19 | 2006-01-11 | 沃纳-兰伯特公司 | 稠合二环或三环氨基酸 |
CN101878193A (zh) * | 2007-09-28 | 2010-11-03 | 第一三共株式会社 | 双环γ-氨基酸衍生物 |
Non-Patent Citations (2)
Title |
---|
GEISEL, M. ET AL.: "Die Cyclopropylcarbinyl-Cyclobutyl-Homoallyl-Umlagerung. I. Teil. Synthese von Tricyclo[3.2.1.0 2, 7]octan-3-ol, endo-und exo-Tri-cyclo [3.2.1.0 3, 6]octan-4-ol und exo-Bicyclo [3.2.1]-oct-2-en-7-ol", HELVETICA CHIMICA ACTA, vol. 56, no. 3, 31 December 1973 (1973-12-31), pages 1046 - 1055, XP055483326 * |
YATES, P. ET AL.: "Decompositjon of 1-Diazo-3-(2, 2, 3-Trimethylcyclo-Pent-3-Enyl) Propan-2-One. A Novel Synthesis and Rearrangement of a Tricyclo[3.2.1.0 3, 6]Octan-4-One", TETRAHEDRON LETTERS, vol. 9, no. 20, 31 December 1968 (1968-12-31), pages 2493 - 2496, XP055483332 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021525789A (ja) * | 2018-07-12 | 2021-09-27 | 四川海思科制▲薬▼有限公司 | 縮合三環性γ−アミノ酸誘導体の組成物及びその調製 |
KR20210028680A (ko) | 2018-07-12 | 2021-03-12 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 융합된 트리사이클릭 감마-아미노산 유도체의 조성물 및 이의 제조 방법 |
KR102515847B1 (ko) * | 2018-07-12 | 2023-03-29 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 융합된 트리사이클릭 감마-아미노산 유도체의 조성물 및 이의 제조 방법 |
JP7222063B2 (ja) | 2018-07-12 | 2023-02-14 | 四川海思科制▲薬▼有限公司 | 縮合三環性γ-アミノ酸誘導体の組成物及びその調製 |
WO2020011257A1 (zh) * | 2018-07-12 | 2020-01-16 | 四川海思科制药有限公司 | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 |
AU2019302611B2 (en) * | 2018-07-12 | 2022-02-17 | Sichuan Haisco Pharmaceutical Co., Ltd. | Composition of Fused Tricyclic gamma-Amino Acid Derivatives and the Preparation Thereof |
EP3822252A4 (en) * | 2018-07-12 | 2021-11-17 | Sichuan Haisco Pharmaceutical Co., Ltd. | COMPOSITION OF A CONDENSED TRICYCLIC GAMMA AMINO ACID DERIVATIVE AND PRODUCTION THEREOF |
CN111918859A (zh) * | 2018-07-12 | 2020-11-10 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用 |
CN112384494A (zh) * | 2018-07-12 | 2021-02-19 | 四川海思科制药有限公司 | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 |
WO2020011258A1 (zh) * | 2018-07-12 | 2020-01-16 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用 |
CN111918859B (zh) * | 2018-07-12 | 2023-06-30 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用 |
CN112384493B (zh) * | 2018-08-09 | 2023-06-06 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的制备方法及中间体 |
WO2020029762A1 (zh) * | 2018-08-09 | 2020-02-13 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的制备方法及中间体 |
CN112384493A (zh) * | 2018-08-09 | 2021-02-19 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的制备方法及中间体 |
TWI777079B (zh) * | 2018-08-09 | 2022-09-11 | 大陸商四川海思科製藥有限公司 | 稠合三環γ-胺基酸衍生物的製備方法及其中間體 |
TWI738162B (zh) * | 2019-01-30 | 2021-09-01 | 大陸商四川海思科製藥有限公司 | 稠合三環氘代衍生物及其組合物和用途 |
CN113316564A (zh) * | 2019-01-30 | 2021-08-27 | 四川海思科制药有限公司 | 一种稠合三环氘代衍生物及其组合物和应用 |
CN113316564B (zh) * | 2019-01-30 | 2023-06-09 | 四川海思科制药有限公司 | 一种稠合三环氘代衍生物及其组合物和应用 |
WO2020155953A1 (zh) * | 2019-01-30 | 2020-08-06 | 四川海思科制药有限公司 | 一种稠合三环氘代衍生物及其组合物和应用 |
WO2020155952A1 (zh) * | 2019-02-01 | 2020-08-06 | 四川海思科制药有限公司 | 一种稠合三环衍生物的制备方法及中间体 |
TWI755667B (zh) * | 2019-02-01 | 2022-02-21 | 大陸商四川海思科製藥有限公司 | 稠合三環衍生物的製備方法及其中間體 |
CN111517932A (zh) * | 2019-02-01 | 2020-08-11 | 四川海思科制药有限公司 | 一种稠合三环衍生物制备方法及中间体 |
CN111517932B (zh) * | 2019-02-01 | 2023-03-24 | 四川海思科制药有限公司 | 一种稠合三环衍生物制备方法及中间体 |
CN111517930B (zh) * | 2019-02-01 | 2023-03-24 | 四川海思科制药有限公司 | 一种稠合三环衍生物制备方法及中间体 |
CN111517930A (zh) * | 2019-02-01 | 2020-08-11 | 四川海思科制药有限公司 | 一种稠合三环衍生物制备方法及中间体 |
WO2021043117A1 (zh) * | 2019-09-03 | 2021-03-11 | 四川海思科制药有限公司 | 2-((1s,2s,3r,6s,8s)-2-(氨甲基)三环[4.2.1.03,8]壬烷-2-基)乙酸苯磺酸盐或其组合物杂质检测方法 |
TWI759845B (zh) * | 2019-09-03 | 2022-04-01 | 大陸商四川海思科製藥有限公司 | ]壬烷-2-基)乙酸苯磺酸鹽或其組合物的雜質檢測方法 |
WO2022017364A1 (zh) | 2020-07-20 | 2022-01-27 | 四川海思科制药有限公司 | 一种稠合三环γ-氨基酸衍生物的缓释药物制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20190046892A (ko) | 2019-05-07 |
AU2017325913A1 (en) | 2019-05-02 |
CN109195945B (zh) | 2022-02-25 |
US10654794B2 (en) | 2020-05-19 |
AU2017325913B2 (en) | 2020-04-09 |
EP3527552B1 (en) | 2022-11-30 |
EP3527552A1 (en) | 2019-08-21 |
CN109195945A (zh) | 2019-01-11 |
KR102335089B1 (ko) | 2021-12-02 |
PT3527552T (pt) | 2023-02-28 |
CA3035121C (en) | 2021-02-16 |
JP7001679B2 (ja) | 2022-02-04 |
EA036525B1 (ru) | 2020-11-19 |
MX2019002915A (es) | 2019-07-18 |
TWI662015B (zh) | 2019-06-11 |
US20190218172A1 (en) | 2019-07-18 |
BR112019004860A2 (pt) | 2019-06-11 |
ES2939260T3 (es) | 2023-04-20 |
CA3035121A1 (en) | 2018-03-22 |
EP3527552A4 (en) | 2020-05-06 |
ZA201901861B (en) | 2020-10-28 |
JP2019532925A (ja) | 2019-11-14 |
EA201990455A1 (ru) | 2019-09-30 |
TW201811733A (zh) | 2018-04-01 |
MY196788A (en) | 2023-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018050046A1 (zh) | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 | |
JP2021193128A (ja) | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 | |
KR100618743B1 (ko) | 융합된 비사이클릭 또는 트리사이클릭 아미노산 | |
BR112019026678A2 (pt) | indolinas espirocíclicas como moduladores de il-17 | |
CN107848952B (zh) | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 | |
KR20170060162A (ko) | 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법 | |
CN106928080B (zh) | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 | |
WO2017107907A1 (zh) | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 | |
EP4339189A1 (en) | Nmda receptor antagonist and use thereof | |
EP3650448A1 (en) | Indole-formamide derivative, preparation method therefor and use thereof in medicine | |
JP2021512909A (ja) | ステロイド系誘導体モジュレーター、その製造方法及び応用 | |
WO2022235859A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
TW201113280A (en) | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS | |
CN113316564B (zh) | 一种稠合三环氘代衍生物及其组合物和应用 | |
WO2022022646A1 (zh) | 含硒五元杂芳环化合物 | |
BR112019004860B1 (pt) | Compostos, estereoisômeros, solvatos, pró-fármacos ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica contendo os mesmos, uso dos referidos compostos e composto intermediário | |
WO2021031594A1 (zh) | 芳环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17850248 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3035121 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019514102 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197008206 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019004860 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017850248 Country of ref document: EP Effective date: 20190415 |
|
ENP | Entry into the national phase |
Ref document number: 2017325913 Country of ref document: AU Date of ref document: 20170912 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112019004860 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190313 |